J&J gets FDA breakthrough therapy status for nipocalimab in Sjogren’s

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

  • Johnson & Johnson (NYSE:JNJ) has received FDA breakthrough therapy designation for its drug candidate nipocalimab in the treatment of moderate-to-severe Sjogren’s disease.
  • The FDA also granted breakthrough therapy designation to nipocalimab earlier this year for hemolytic disease of the fetus

Leave a Reply

Your email address will not be published. Required fields are marked *